• Bisphosphonates produce varying results during drug holidays

    5 monthes ago - By Healio

    Postmenopausal women assigned alendronate therapy are more likely to experience a loss of bone mineral density or an increase in bone turnover markers during a 3-year drug holiday than women assigned zoledronic acid, according to a post hoc analysis of two large trials published in the Journal of Bone and Mineral Research.
    “After stopping therapy, former alendronate users had greater BMD loss and increases in bone turnover compared to former zoledronic acid users,” Tiffany Y. Kim, MD, an advanced fellow in women's health with the San Francisco VA Health Care System and the
    Read more ...